Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Optimal designs for two‐stage genome‐wide association studies

Optimal designs for two‐stage genome‐wide association studies Genome‐wide association (GWA) studies require genotyping hundreds of thousands of markers on thousands of subjects, and are expensive at current genotyping costs. To conserve resources, many GWA studies are adopting a staged design in which a proportion of the available samples are genotyped on all markers in stage 1, and a proportion of these markers are genotyped on the remaining samples in stage 2. We describe a strategy for designing cost‐effective two‐stage GWA studies. Our strategy preserves much of the power of the corresponding one‐stage design and minimizes the genotyping cost of the study while allowing for differences in per genotyping cost between stages 1 and 2. We show that the ratio of stage 2 to stage 1 per genotype cost can strongly influence both the optimal design and the genotyping cost of the study. Increasing the stage 2 per genotype cost shifts more of the genotyping and study cost to stage 1, and increases the cost of the study. This higher cost can be partially mitigated by adopting a design with reduced power while preserving the false positive rate or by increasing the false positive rate while preserving power. For example, reducing the power preserved in the two‐stage design from 99 to 95% that of the one‐stage design decreases the two‐stage study cost by ∼15%. Alternatively, the same cost savings can be had by relaxing the false positive rate by 2.5‐fold, for example from 1/300,000 to 2.5/300,000, while retaining the same power. Genet. Epidemiol. 2007. © 2007 Wiley‐Liss, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Genetic Epidemiology Wiley

Optimal designs for two‐stage genome‐wide association studies

Download PDF
13 pages

Loading next page...
 
/lp/wiley/optimal-designs-for-two-stage-genome-wide-association-studies-IBqFqQkD1o

References (20)

Publisher
Wiley
Copyright
Copyright © 2007 Wiley‐Liss, Inc., A Wiley Company
ISSN
0741-0395
eISSN
1098-2272
DOI
10.1002/gepi.20240
pmid
17549752
Publisher site
See Article on Publisher Site

Abstract

Genome‐wide association (GWA) studies require genotyping hundreds of thousands of markers on thousands of subjects, and are expensive at current genotyping costs. To conserve resources, many GWA studies are adopting a staged design in which a proportion of the available samples are genotyped on all markers in stage 1, and a proportion of these markers are genotyped on the remaining samples in stage 2. We describe a strategy for designing cost‐effective two‐stage GWA studies. Our strategy preserves much of the power of the corresponding one‐stage design and minimizes the genotyping cost of the study while allowing for differences in per genotyping cost between stages 1 and 2. We show that the ratio of stage 2 to stage 1 per genotype cost can strongly influence both the optimal design and the genotyping cost of the study. Increasing the stage 2 per genotype cost shifts more of the genotyping and study cost to stage 1, and increases the cost of the study. This higher cost can be partially mitigated by adopting a design with reduced power while preserving the false positive rate or by increasing the false positive rate while preserving power. For example, reducing the power preserved in the two‐stage design from 99 to 95% that of the one‐stage design decreases the two‐stage study cost by ∼15%. Alternatively, the same cost savings can be had by relaxing the false positive rate by 2.5‐fold, for example from 1/300,000 to 2.5/300,000, while retaining the same power. Genet. Epidemiol. 2007. © 2007 Wiley‐Liss, Inc.

Journal

Genetic Epidemiology – Wiley

Published: Nov 1, 2007

Keywords: genome‐wide association; two‐stage design; association; optimal design

There are no references for this article.